On the same note, the early introduction of ARNI and SGLT2 inhibitors may be considered in patients with reduced ejection fraction [205], and PCSK9i can be prescribed immediately after an acute myocardial infarction [206]. This evidence concerns the gene SLC5A2 and acute myocardial infarction.